Cholesterol as a predictor of progression in diabetic renal disease

Contributions to Nephrology

Volumn 120, Issue , 1997, Pages 39-47

  Ravid, Mordchai ^a,b   Rachmani, Rita ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ANIMAL; BLOOD; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERLIPIDEMIAS;

EID: 0030628935     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000059822     Document Type: Article

References (58)

1. Keane WF, Kasiske BL, O'Donnell MP: Hyperlipidemia and the progression of renal disease. Am J Clin Nutr 1988;47:157-160.
2. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP: Hyperlipidemia and progressive renal disease. Kidney Int 1991;39(suppl 31):S41-S48.
3. Roullef JB, Lacour B, Yvert JP, Prat JJ, Drueke T: Factors of increase in serum triglyceride-rich lipoproteins in uremic rats. Kidney Int 1985;27:420-425.
4. Kasiske BL, Cleary MP, Keane WF: Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 1995;106:598-604.
5. Silveiro SP, Friedman R, Gross FL: Glomerular hyperfiltration in NIDDM patients without overt proteinuria. Diabetes Care 1993;16:115-119.
6. Jerums G, Allen TJ, Tsalamandris C, Akdenis A, Shinka A, Gilbert R, Cooper ME: Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia 1993;36:1037-1044.
7. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF: Renal injury of diet induced hypercholesterolemia in rats. Kidney Int 1990;37:880-891.
8. Kasiske BL, Garris WJ, Kean WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988;62:367-374.
9. Moorhead JF, El Nakos M, Chan MK, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;ii:1309-1310.
10. Rossing P, Hommel E, Smidy UM, Parving HH: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nethropathy during antihypertensive treatment. Diabetologia 1994;37:511-516.
11. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M: Long term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int 1994;45(suppl 45):S161-S164.
12. Hostetter TH, Rennke HG, Brenner BM: The case for inrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375-380.
13. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-1930.
14. Ravid M, Savin H, Jutrin I, Benal T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-581.
15. Parving HH: Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy and endothelial permeability in diabetes mellitus. Diabetes Care 1991;14:260-269.
16. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF: Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990;37:880-891.
17. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP: Hyperlipidemia and progressive renal disease. Kidney Int 1991;39(suppl 31):S541-S548.
18. Kuletsky S: Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 1975;80:129-142.
19. Verbeuren TJ, Jordeans FH, Zonnenkeyn LL, Van Hove CE, Coene MC, Hermann AG: Effect of hypercholesterolemia on vascular reactivity in the rabbit. Circ Res 1986;58:552-564.
20. Smith-Barbaro P, Quinn MR, Fisher H, Hegsted DM: The effect of dietary fat and salt on blood pressure, renal and aortic prostglandins. Nutr Res 1981;1:177-287.
21. Sreeharan N, Jayakody RL, Senaratne MPJ, Thompson ABR, Kappagoda CT: Endothelium dependent relaxation and experimental atherosclerosis in the rabbit aorta. Can J Physiol Pharmacol 1986;64:1451-1453.
22. Kaplan R, Aynedjian HS, Bank N, Schlorndorff DO: Cholesterol feeding causes renal vasoconstriction via oxidized lipoprotein activation of thromboxane. Kidney Int 1990;37:371A.
23. Mulcahy WS, Smith JB, Selak M, Krishna GG: Cytotoxicity of low density lipoprotein (LDL) in cultured rat mesangial cells (MC) (abstract). Kidney Int 1990;37:514.
24. Hovig T, Gjune E: Familial lecitin-cholestcrol acyltransferase deficiency: Ultrastructural studies on lipid deposition and tissue reactions. Scand J Clin Lab Invest 1974;33(suppl 137):135-146.
25. Shibata T, Kaneko N, Haya Y, Saito T, Sakaguchi H: A case of lipoprotein glomerulopathy. Acta Pathol Jpn 1990;40:448-457.
26. Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: A renal risk factor in diabetic nephropathy. Am J Kidney Dis 1993;22:196-201.
27. Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensin converting enzyme inhibition in diabetic nephropathy: Ten years' experience. Am J Kidney Dis 1995;26:99-107.
28. Lahdenpera S, Groop PH, Tilly-Kiesi M, Kaasi T: LDL subclasses in IDDM patients: Relation to diabetic nephropathy. Diabetologia 1994;37:681-688.
29. Knobl P, Dietschmann P, Schnak C, Prager R, Schernthaner G: Apolipoprotein(a) levels in patients with type 1 diabetes mellitus are unrelated to metabolic control or vascular disease. Wien Klin Wochenschr 1994;106:728-732.
30. Myrup B, Mathiesen ER, Ronn B, Deckert T: Endothelial function and serum lipids in the course of developing microalbuminuria in insulin dependent diabetes mellitus. Diabetes Res 1994;26:33-39.
31. Krolewski AS, Warram JH, Christlieb AR: Hypercholesterolemia: A determinant of renal function loss and death in IDDM patients with nephropathy. Kidney Int 1994;45(suppl 45):S125-S131.
32. Diabetic Retinopathy Study: Report number 6: Design, methods and baseline results. Invest Opthalmol Vis Sci 1981;21:183-188.
33. Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982;285:685-688.
34. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987;294:1443-1447.
35. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effect of angiotensin-converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 1986;293:467-470.
36. Hollenberg NK, Raij L: Angiotensin-converting enzyme inhibition and renal protection. Arch Intern Med 1993;153:2426-2435.
37. Reblink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA: Partial remission of nephrotic syndrome in patients on long term simvastatin. Lancet 1990;i:1045-1046.
38. Sweny P, Wheeler DC, Luis F, Amin NS, Barradas MA, Jeremy JY, Mikhailidis DP, Varghese Z, Fernando ON: Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. Nephrol Dial Transplant 1989;4:1070-1075.
39. Hommel E, Andersen P, Gall MA, Neilsen F, Jensen B, Rossing P, Dyerberg J, Parving HH: Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephrophy. Diabetologia 1992;35:447-451.
40. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
41. Haaber AB, Kofoed-Enevoldsen A, Jensen T: The prevalence of hyercholesterolemia and its relationship with albuminuria in insulin dependent diabetic patients: An epidemiological study. Diabetic Med 1992;9:557-561.
42. Low MR, Wald JN, Thompson SG: By how much and how quickly does reduction of serum cholesterol concentration lower risk of ischemic heart disease. Br Med J 1994;308:367-373.
43. Low MR, Wald NJ, Hackshaw A, Bailey A: Systematic underestimation of concentration and ischemic heart disease in observational studies: Data from the BUPA study. BMJ 1994;308:363-366.
44. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
45. Ravid M, Neuman L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE-inhibitors. Kidney Int 1995;47:907-910.
46. Yokota C, Kimura G, Inenaga T, Kawano Y: Risk factors for progression of diabetic nephropathy. Am J Nephrol 1995;15:488-492.
47. Alzaid AA, Sobhi S, De-Silva V: Prevalence of microalbuminuria in Saudi Arabians with non-insulin dependent diabetes mellitus: A clinic based study. Diabetes Res Clin Pract 1994;26:115-120.
48. Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P: Effect of metabolic factors and blood presssure on kidney function in proteinuric type II (non-insulin dependent) diabetic patients. Diabetologia 1993;36:1051-1056.
49. Shank ML, Del Prato S, Defronzo RA: Bedtime insulin/daytime glipizide: Effective therapy for sulfonilurea failure in NIDDM. Diabetes 1995;44:165-172.
50. Viswanathan VV, Snehalatha C, Ranachandrna A, Viswanathan M: Proteinuria in NIDDM in South India: Analysis of predictive factors. Diabetes Res Clin Pract 1995;28:41-46.
51. Lam KS, Cheng IK, Jenus ED, Pang RW: Cholesterol lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604-609.
52. Keilani T, Schlueter W, Battle D: Selected aspects of ACE inhibitor therapy for patients with renal disease: Impact on proteinuria lipids and potassium. J Clin Pharmacol 1995;35:87-97.
53. Ravid M, Brosh D, Ravid D, Rachmani R: Predictive factors for subsequent loss of kidney function and albuminuria in NIDDM. Ann Int Med, in press.
54. Chobanien AV: Hypertension, antihypertensive drugs and atherosclerosis: Mechanisms and clinical implications. J Clin Hypertens 1986;3:148-157.
55. Moorkad JF: Lipids and progressive kidney disease. Kidney Int 1991;39(suppl 31):535-540.
56. Warwick GL, Caslake MJ, Boulton-Jones JM, Dagen M, Packard CJ, Shepherd J: Low density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990;39:187-192.
57. Lebovitz HE, Wiegmann TB, Cnaan A, Schwartz SZ, Mengel MC, Segal R, Versaggi JA, Bolton WK: Renal protective effect of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 1994;45(suppl 45):S150-S155.
58. Ravid M, Savin H, Lang R, Jutrin I, Ludvinovski S, Lishner M: Proteinuria, renal impairment, metabolic control and blood pressure in type 2 diabetes mellitus: A 14-year follow-up report on 195 patients. Arch Intern Med 1992;152:1225-1229.